Company / Cash & Equivalents
CASTLE BIOSCIENCES INC Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$116.7M
FY2025
5-year range
$98.8M / $329.6M
FY2021-FY2025
Trend
-2.5%
vs FY2024
Sector context
#104 of 148
Health Care
What the data says
At $117M, CASTLE BIOSCIENCES INC's cash & equivalents ranks #104 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 8 years, ranging from $4M in FY2018 to $410M in FY2020.
Based on SEC 10-K filings.
$117M in FY2025 with a 5-year CAGR of -22.2%.
Improved from $99M to $117M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -1.7%
- 5-Year CAGR
- -22.2%
- 10-Year CAGR
- -
Sector benchmark
#104 of 148 in Health CareTop 70% of 148This company $116.7M Sector average $1.2B
▼
-90.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -22.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 2.5% year-over-year.
- Ranks #104 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $116.7M | -2.5% |
| FY2024 | $119.7M | +21.1% |
| FY2023 | $98.8M | -19.6% |
| FY2022 | $122.9M | -62.7% |
| FY2021 | $329.6M | -19.6% |
| FY2020 | $409.9M | +314.6% |
| FY2019 | $98.8M | +2106.9% |
| FY2018 | $4.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026